{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:19:25Z","timestamp":1767651565432,"version":"3.33.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1136\/ard.62.10.969","type":"journal-article","created":{"date-parts":[[2003,9,12]],"date-time":"2003-09-12T19:01:04Z","timestamp":1063393264000},"page":"969-975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women"],"prefix":"10.1016","volume":"62","author":[{"given":"J A","family":"Stakkestad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L I","family":"Benevolenskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J J","family":"Stepan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Skag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Nordby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Oefjord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Burdeska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Jonkanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.62.10.969_bib1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJM199208273270908","article-title":"The prevention and treatment of osteoporosis","volume":"327","author":"Riggs","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.62.10.969_bib2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jbmr.5650070608","article-title":"Appendicular bone mineral and a woman\u2019s lifetime risk of hip fractures","volume":"7","author":"Black","year":"1992","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.62.10.969_bib3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF01623782","article-title":"Guidelines for diagnosis and management of osteoporosis","volume":"7","author":"Kanis","year":"1997","journal-title":"Osteoporos Int"},{"key":"10.1136\/ard.62.10.969_bib4","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and outcomes of osteoporotic fractures","volume":"359","author":"Cummings","year":"2002","journal-title":"Lancet"},{"issue":"suppl 2a","key":"10.1136\/ard.62.10.969_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(05)80037-3","article-title":"The economic and human costs of osteoporotic fracture","volume":"98","author":"Barret-Connor","year":"1995","journal-title":"Am J Med"},{"key":"10.1136\/ard.62.10.969_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1136\/ard.62.10.969_bib7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"suppl 2","key":"10.1136\/ard.62.10.969_bib8","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/PL00004164","article-title":"Bisphosphonates: pharmacology, mechanisms of action and clinical uses","volume":"9","author":"Russell","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1136\/ard.62.10.969_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00002512-199915040-00004","article-title":"New bisphosphonates in the treatment of bone diseases","volume":"15","author":"Gatti","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1136\/ard.62.10.969_bib10","series-title":"Osteoporosis","first-page":"631","article-title":"Bisphosphonates in the management of postmenopausal osteoporosis","author":"Papapoulos","year":"2001"},{"key":"10.1136\/ard.62.10.969_bib11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.62.10.969_bib12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00003495-199142060-00003","article-title":"Bisphosphonates: pharmacology and use in the treatment of tumor-induced hypercalcaemia and metastatic bone disease","volume":"42","author":"Fleisch","year":"1991","journal-title":"Drugs"},{"issue":"suppl 3","key":"10.1136\/ard.62.10.969_bib13","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/BF01623002","article-title":"Clinical pharmacology of alendronate sodium","volume":"3","author":"Gertz","year":"1993","journal-title":"Osteoporosis Int"},{"key":"10.1136\/ard.62.10.969_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse effects of bisphosphonates. A comparative review","volume":"14","author":"Adami","year":"1996","journal-title":"Drug Safety"},{"issue":"suppl 11","key":"10.1136\/ard.62.10.969_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90232-5","article-title":"Dosing regimens and main adverse events of bisphosphonates","volume":"28","author":"Body","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1136\/ard.62.10.969_bib16","first-page":"127","article-title":"The impact of adherence to osteoporosis therapy on fracture rates in actual practice","volume":"5","author":"Caro","year":"2002","journal-title":"Value in Health"},{"key":"10.1136\/ard.62.10.969_bib17","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)"},{"issue":"suppl 1","key":"10.1136\/ard.62.10.969_bib18","first-page":"S32","article-title":"Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study [abstract]","volume":"13","author":"Kendler","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1136\/ard.62.10.969_bib19","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","article-title":"Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study","volume":"24","author":"Simon","year":"2002","journal-title":"Clin Ther"},{"key":"10.1136\/ard.62.10.969_bib20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thi\u00e9baud","year":"1997","journal-title":"Am J Med"},{"issue":"suppl 1","key":"10.1136\/ard.62.10.969_bib21","first-page":"S17","article-title":"Three-monthly intravenous ibandronate bolus injections: a novel treatment regimen to prevent postmenopausal bone loss [abstract]","volume":"13","author":"Stakkestad","year":"2002","journal-title":"Osteoporos Int"},{"issue":"suppl 1","key":"10.1136\/ard.62.10.969_bib22","first-page":"S14","article-title":"Three-monthly 2 mg intravenous ibandronate bolus injections significantly increase BMD in women with postmenopausal osteoporosis [abstract]","volume":"13","author":"Adami","year":"2002","journal-title":"Osteoporos Int"},{"issue":"suppl 1","key":"10.1136\/ard.62.10.969_bib23","first-page":"S472","article-title":"Three-monthly 2 mg intravenous ibandronate injections restore bone turnover to premenopausal levels [abstract]","volume":"17","author":"Adami","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"suppl 2","key":"10.1136\/ard.62.10.969_bib24","first-page":"S209","article-title":"A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): results of a 3-year trial [abstract]","volume":"11","author":"Recker","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1136\/ard.62.10.969_bib25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled, dose-finding study","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"key":"10.1136\/ard.62.10.969_bib26","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","article-title":"Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis","volume":"16","author":"Riis","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.62.10.969_bib27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/rheumatology\/keg205","article-title":"Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis","volume":"42","author":"Ringe","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.62.10.969_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jbmr.5650110506","article-title":"Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection","volume":"11","author":"Pecherstorfer","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.62.10.969_bib29","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 6","key":"10.1136\/ard.62.10.969_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0093-7754(01)90262-3","article-title":"Zoledronic acid in cancer patients with bone metastases: results of phase I and II trials","volume":"28","author":"Berenson","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1136\/ard.62.10.969_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002018-199921050-00004","article-title":"Comparative tolerability of drug therapies for hypercalcaemia of malignancy","volume":"21","author":"Zoja","year":"1999","journal-title":"Drug Safety"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724088496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724088496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.62.10.969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T23:33:16Z","timestamp":1737243196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724088496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["S0003496724088496"],"URL":"https:\/\/doi.org\/10.1136\/ard.62.10.969","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2003,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.62.10.969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Copyright 2003 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}